Nova Eye Medical Limited (ASX:EYE) has applied for quotation of 7,000 fully paid ordinary shares on the Australian Securities Exchange, issued on 19 November 2026 following the conversion of performance rights held under the company's employee incentive scheme.
Key Points
- 7,000 ordinary fully paid shares (ASX:EYE) applied for quotation with an issue date of 19 November 2026
- Securities were issued via conversion of performance rights (EYEAC) under the company's employee incentive scheme
- No cash consideration was received; the estimated value of consideration per security is recorded as $0.00
- Following quotation, total quoted ordinary shares on issue will be 284,928,093, with 42,000 performance rights remaining unquoted
Performance Rights Conversion Details
According to the filing, the 7,000 ordinary fully paid shares were issued through the conversion of performance rights classified under ASX security code EYEAC. The securities are described as being issued under an employee incentive scheme and are not subject to a restriction on transfer, or are to be quoted notwithstanding any such restriction. The filing states the issue was made under an exception in Listing Rule 7.2, specifically exception 13, meaning no security holder approval was required under Listing Rule 7.1. The securities are stated to rank equally in all respects from their issue date with existing issued securities in the same class.
Consideration and Key Management Personnel
The filing discloses that no cash consideration was provided for the 7,000 securities, with the consideration described as the conversion of performance rights and the estimated value per security recorded as $0.000000. The filing also states that the securities being issued are not being issued to key management personnel or an associate of key management personnel. The issue falls within an existing class of quoted securities on ASX, being ordinary fully paid shares under the ticker EYE.
Issued Capital Following Quotation
Upon completion of the quotation of the 7,000 ordinary shares, Nova Eye Medical's total quoted ordinary fully paid securities on issue will stand at 284,928,093 shares. The company's unquoted securities will comprise 42,000 performance rights remaining on issue under the EYEAC security code. The filing notes that the figures for issued capital are automatically generated and may not reflect current issued capital if other forms are simultaneously being processed by ASX at the time of lodgement.



Please wait processing your request...